Clinical pharmacokinetics and pharmacodynamics of inhaled insulin

Clinical Pharmacokinetics
John S PattonMichael A Eldon

Abstract

The benefits of intensive insulin therapy in the prevention of complications in patients with diabetes mellitus are now well established. However, the current methods of insulin administration fall well short of the ideal. Consequently, alternative routes of insulin administration have been investigated. The pulmonary route has received the most attention, helped by advances in inhaler devices and insulin formulation technology. As a result, several insulin inhalation systems are at varying stages of development, with one already filed for marketing approval in Europe. Knowledge of the pharmacokinetic and pharmacodynamic characteristics of the various inhaled insulin formulations will help to determine their positioning in current and evolving diabetes treatment strategies. For instance, a rapid onset and short duration of action would be desirable for use in postprandial glucose control. Pharmacokinetic studies with inhaled insulin reveal that serum insulin concentrations peak earlier and decay more rapidly following inhalation compared with subcutaneously administered regular insulin, and pharmacodynamic studies measuring glucose infusion rate under euglycaemic glucose clamp show corresponding rapid changes in glucose control...Continue Reading

Citations

Nov 28, 2007·Pharmaceutical Research·Reinhard Vehring
Jun 1, 2005·Archives of Medical Research·Francisco J Gómez-Pérez, Juan A Rull
Oct 22, 2013·International Journal of Pharmaceutics·Paul ZarogoulidisKonstantinos Zarogoulidis
Jul 8, 2008·Journal of Feline Medicine and Surgery·Amy E DeClueCarol R Reinero
Dec 30, 2006·Nature Reviews. Drug Discovery·John S Patton, Peter R Byron
Feb 3, 2007·The New England Journal of Medicine·Graham T McMahon, Ronald A Arky
Jan 3, 2006·Diabetes Technology & Therapeutics·Steven WhiteNancy J Harper
Jul 10, 2007·Diabetes Technology & Therapeutics·Irl B Hirsch
Jul 10, 2007·Diabetes Technology & Therapeutics·Joseph D Brain
Mar 17, 2011·Diabetes Technology & Therapeutics·Masami NemotoTakashi Sasaki
Mar 23, 2006·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·Sunalene G Devadason
Mar 23, 2006·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·Mark L Everard
May 12, 2010·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Preshit DandekarAnurag Mehra
Dec 8, 2010·Journal of Aerosol Medicine and Pulmonary Drug Delivery·John S PattonCarsten Ehrhardt
Jun 22, 2011·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Paul ZarogoulidisEfstratios Maltezos
Jun 30, 2006·International Journal of Clinical Practice·S Bellary, A H Barnett
Sep 20, 2007·International Journal of Clinical Practice·A H BarnettUNKNOWN Exubera Phase 3 Study Group
Dec 23, 2008·The Journal of Pharmacology and Experimental Therapeutics·Dale S EdgertonThomas R Strack
Jul 26, 2005·Archives of Disease in Childhood·A Bush
Mar 25, 2006·American Journal of Respiratory and Critical Care Medicine·John G Teeter, Richard J Riese
Mar 18, 2010·Vascular Health and Risk Management·Lucy D Mastrandrea
Aug 24, 2007·Clinical Pharmacokinetics·Jasper Dingemanse, Silke Appel-Dingemanse
May 1, 2008·Indian Journal of Pharmaceutical Sciences·M M Al-Tabakha, A I Arida
Jul 6, 2014·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·M HoppentochtA H de Boer
Mar 26, 2016·International Journal of Pharmaceutical Investigation·Rima B ShahViral N Shah
Dec 24, 2005·Expert Opinion on Drug Delivery·Vincent J SullivanBrandi Ford
Oct 4, 2006·Expert Opinion on Drug Metabolism & Toxicology·Chantal Mathieu
Oct 27, 2012·Expert Opinion on Drug Delivery·Sandra SoaresBruno Sarmento
Apr 23, 2008·Expert Opinion on Drug Delivery·Sinéad M RyanDavid J Brayden
Dec 9, 2014·Expert Opinion on Drug Delivery·Jahidur RashidFakhrul Ahsan
Nov 22, 2005·Expert Opinion on Drug Delivery·Andreas Pfützner, Thomas Forst
Apr 17, 2014·Advanced Drug Delivery Reviews·M HoppentochtA H de Boer
Feb 27, 2010·Journal of Pharmaceutical Sciences·Jasmine M TamKeith P Johnston
Feb 9, 2007·Journal of Pharmaceutical Sciences·Negar SadrzadehCynthia L Stevenson
Jul 17, 2015·Journal of Pharmaceutical Sciences·Erica BäckströmMarkus Fridén
Jan 3, 2012·Pulmonary Pharmacology & Therapeutics·Peter MayerKurt Racké
Aug 28, 2010·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Flore Depreter, Karim Amighi
Oct 23, 2010·Revue des maladies respiratoires·M-H Becquemin, J-P Chaumuzeau
Sep 8, 2009·Research in Social & Administrative Pharmacy : RSAP·Sharrel L PintoDavid Lesch
Mar 21, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Maryam AmidiWim Jiskoot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.